Floatz logo

Sofosbuvir

HCV Related Cirrhosis

Institute of Liver and Biliary Sciences, IndiaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the HCV Related Cirrhosis cohort.

Asset / SponsorPhaseRating
CARVEDILOL
Tianjin Second People's Hospital
Phase 3B
UMBELLATINE
Tianjin Second People's Hospital
Phase 3B
Rosuvastatin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2CCC
Ribavirin
Institute of Liver and Biliary Sciences, India
N/AD
Pri-724
Komagome Hospital
Phase 1NR

Same molecule, other indications

Sofosbuvir is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative ·
81 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →